Alpha Cognition

CEO Michael McFadden brings ~30 years of neurology/psychiatry commercialization experience, including senior roles at Avanir and Urovant; team depth in market access and LTC is evident. Governance is standard for a small‑cap biotech. Insider ownership is present but not controlling.

Execution so far shows discipline in channel focus and payer contracting, though credibility will ultimately be judged on conversion of real‑world data into coverage and sustained prescriber behavior.